MiR-26a functions as an endogenous inhibitor of the TGF-β1/Smad signaling pathway, and its downregulation in IPF and pulmonary fibrosis mice models leads to the upregulation of CTGF, COL1A1, and COL3A1. Here, COL3A1 is linked to idiopathic pulmonary fibrosis.